<div class="welcome-screen" id="welcomeScreen">
    <div class="welcome-banner">
        <h1 id="welcome-title">Welcome to the page on anticoagulants!</h1>
        <p id="welcome-description">Explore the following topics to enhance your knowledge.</p>
    </div>
    
    <div class="explanation-card">
        <h1>Introduction to Anticoagulants</h1>
        <h2>Historical Perspective</h2>
        <p>The discovery of anticoagulants revolutionized medicine in the 20th century. <b>Heparin</b>, the first clinically used anticoagulant, was isolated from dog liver in 1916 by Jay McLean and William Henry Howell. <b>Warfarin</b>, derived from spoiled sweet clover causing cattle bleeding in the 1920s, was introduced for human use in the 1950s after its mechanism was understood. The development of <b>low-molecular-weight heparins (LMWHs)</b> in the 1980s and <b>direct oral anticoagulants (DOACs)</b> in the 2000s marked major therapeutic advances.</p>

        <h2>Hemostasis Physiology</h2>
        <p>Normal hemostasis involves a delicate balance between <b>procoagulant</b> and <b>anticoagulant</b> pathways. The <b>vascular endothelium</b> maintains this balance by producing anticoagulants (thrombomodulin, heparan sulfate) and inhibitors (tissue factor pathway inhibitor, TFPI). When injury occurs, <b>platelet adhesion</b> (via vWF-GPIb interaction) and <b>coagulation cascade</b> activation lead to fibrin clot formation. The coagulation cascade consists of the <b>intrinsic</b> (contact activation) and <b>extrinsic</b> (tissue factor) pathways converging at factor Xa.</p>

        <h2>Pathophysiology of Thrombosis</h2>
        <p>Virchow's triad describes three factors predisposing to thrombosis: <b>endothelial injury</b> (e.g., atherosclerosis), <b>stasis</b> (e.g., atrial fibrillation, immobility), and <b>hypercoagulability</b> (e.g., factor V Leiden). Arterial thrombi are platelet-rich ("white clots") while venous thrombi are fibrin/red cell-rich ("red clots"). This distinction guides anticoagulant choice - <b>antiplatelets</b> for arterial thrombosis, <b>anticoagulants</b> for venous thrombosis.</p>

        <div class="mnemonic">
            <b>Mnemonic: "CLOTS" for Virchow's Triad</b><br>
            <b>C</b> - Circulatory stasis<br>
            <b>L</b> - Loss of endothelial integrity<br>
            <b>O</b> - Overactive coagulation<br>
            <b>T</b> - Thrombophilia<br>
            <b>S</b> - Sluggish blood flow
        </div>
    </div>

    <div class="question-card">
        <h1>Question 1</h1>
        <p>Which component of Virchow's triad is most directly addressed by anticoagulant therapy?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Endothelial injury</li>
            <li data-answer="correct">Hypercoagulability</li>
            <li data-answer="wrong">Stasis</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 2</h1>
        <p>Which historical event led to the discovery of warfarin?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Observation of bleeding in sailors eating citrus fruits</li>
            <li data-answer="correct">Cattle dying from hemorrhagic disease after eating spoiled sweet clover</li>
            <li data-answer="wrong">Studies of snake venom coagulation effects</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Vitamin K Antagonists (VKAs)</h1>
        <h2>Mechanism of Action</h2>
        <p><b>Warfarin</b>, the prototypical VKA, inhibits <b>vitamin K epoxide reductase</b> (VKOR), preventing recycling of oxidized vitamin K to its reduced active form. This impairs Î³-carboxylation of <b>vitamin K-dependent clotting factors</b> (II, VII, IX, X) and anticoagulant proteins (C, S). The effect is delayed (2-3 days) due to existing factor stores. Warfarin's effect is monitored via <b>INR</b> (International Normalized Ratio), which primarily reflects factor VII activity early on (short half-life) and factors II, IX, X later.</p>

        <h2>Indications</h2>
        <p>VKAs remain first-line for:</p>
        <ol>
            <li><b>Mechanical heart valves</b> (DOACs contraindicated due to risk of valve thrombosis)</li>
            <li><b>Antiphospholipid syndrome</b> (especially triple-positive with arterial thrombosis)</li>
            <li>Chronic thromboembolic pulmonary hypertension (CTEPH)</li>
            <li>Patients with severe renal impairment (CrCl <15-30 mL/min) where DOACs are contraindicated</li>
        </ol>

        <h2>Pharmacokinetics</h2>
        <p>Warfarin is <b>99% protein-bound</b> (mainly albumin), metabolized by <b>CYP2C9</b> (major) and CYP3A4/CYP1A2 (minor). Genetic polymorphisms in <b>CYP2C9</b> (poor metabolizers) and <b>VKORC1</b> (target sensitivity) affect dosing. The half-life is 20-60 hours, allowing once-daily dosing. Onset is delayed, requiring bridging with heparin/LMWH when treating acute thrombosis.</p>

        <h2>Side Effects & Interactions</h2>
        <p>Major risks include <b>bleeding</b> (1-3%/year major bleeding) and <b>skin necrosis</b> (rare, due to transient hypercoagulability from protein C/S inhibition). Numerous interactions occur via:</p>
        <ol>
            <li><b>Enhanced effects</b>: CYP2C9 inhibitors (amiodarone, fluconazole), vitamin K deficiency (antibiotics killing gut flora), malnutrition</li>
            <li><b>Reduced effects</b>: CYP2C9 inducers (rifampin, carbamazepine), high vitamin K intake (leafy greens)</li>
        </ol>

        <div class="mnemonic">
            <b>Mnemonic: "WARFARIN" for Major Drug Interactions</b><br>
            <b>W</b> - Wine (alcohol)<br>
            <b>A</b> - Antibiotics (especially ciprofloxacin)<br>
            <b>R</b> - Rifampin<br>
            <b>F</b> - Fluconazole<br>
            <b>A</b> - Amiodarone<br>
            <b>R</b> - Ritonavir<br>
            <b>I</b> - NSAIDs (increased bleeding risk)<br>
            <b>N</b> - Nutritional supplements (vitamin K)
        </div>
    </div>

    <div class="question-card">
        <h1>Question 3</h1>
        <p>Why does warfarin require 2-3 days to achieve full anticoagulant effect?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">It must accumulate to therapeutic serum levels</li>
            <li data-answer="correct">Existing vitamin K-dependent clotting factors must be cleared</li>
            <li data-answer="wrong">Time is needed for hepatic enzyme induction</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 4</h1>
        <p>A patient on warfarin develops necrotic skin lesions on the breasts/buttocks on day 3 of therapy. What is the most likely mechanism?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Allergic vasculitis</li>
            <li data-answer="correct">Transient hypercoagulability due to protein C/S inhibition</li>
            <li data-answer="wrong">Direct toxic effect of warfarin metabolites</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Direct Oral Anticoagulants (DOACs/NOACs)</h1>
        <h2>Classification & Mechanism</h2>
        <p>DOACs directly inhibit specific coagulation factors:</p>
        <ol>
            <li><b>Direct thrombin (IIa) inhibitors</b>: Dabigatran</li>
            <li><b>Direct factor Xa inhibitors</b>: Rivaroxaban, Apixaban, Edoxaban, Betrixaban</li>
        </ol>
        <p>Unlike warfarin, they have <b>predictable pharmacokinetics</b> (fixed dosing), <b>rapid onset</b> (1-4 hours), and <b>fewer interactions</b> (no CYP450 metabolism for dabigatran). They don't require routine monitoring but have limited reversal options (idarucizumab for dabigatran, andexanet alfa for Xa inhibitors).</p>

        <h2>Indications</h2>
        <p>DOACs are approved for:</p>
        <ol>
            <li><b>Non-valvular atrial fibrillation</b> (superior to warfarin for intracranial bleed risk)</li>
            <li><b>VTE treatment/prophylaxis</b> (non-inferior to warfarin with less bleeding)</li>
            <li><b>Post-orthopedic thromboprophylaxis</b> (rivaroxaban, apixaban)</li>
        </ol>

        <h2>Pharmacokinetics</h2>
        <p>DOACs have varying renal excretion: dabigatran (80%) > edoxaban (50%) > rivaroxaban (35%) > apixaban (25%). Apixaban has dual excretion (feces 55%, urine 25%). Most are P-gp substrates (avoid with strong P-gp inducers/inhibitors in renal impairment). Half-lives range from 5-17 hours (shorter than warfarin), requiring BID dosing for some.</p>

        <h2>Advantages & Limitations</h2>
        <p><b>Advantages</b> over warfarin include no dietary restrictions, fewer interactions, and predictable effects. <b>Limitations</b> include:</p>
        <ol>
            <li>Contraindicated in severe renal impairment (except apixaban to CrCl 15 mL/min)</li>
            <li>No proven efficacy in mechanical valves/antiphospholipid syndrome</li>
            <li>Higher cost and lack of reliable monitoring assays</li>
        </ol>

        <div class="mnemonic">
            <b>Mnemonic: "DOACs RULE" for When to Choose DOACs</b><br>
            <b>D</b> - Direct acting (no monitoring)<br>
            <b>O</b> - Once/twice daily dosing<br>
            <b>A</b> - Atrial fibrillation (non-valvular)<br>
            <b>C</b> - Convenient (few interactions)<br>
            <b>S</b> - Safe (lower intracranial bleed risk)<br>
            <b>R</b> - Renal function must be checked<br>
            <b>U</b> - Urgent procedures may need reversal<br>
            <b>L</b> - Limited in mechanical valves<br>
            <b>E</b> - Expensive
        </div>
    </div>

    <div class="question-card">
        <h1>Question 5</h1>
        <p>Which DOAC is least dependent on renal excretion and may be used in severe renal impairment (CrCl 15-29 mL/min)?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Dabigatran</li>
            <li data-answer="correct">Apixaban</li>
            <li data-answer="wrong">Edoxaban</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 6</h1>
        <p>Why are DOACs contraindicated in mechanical heart valves?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">They cause valve calcification</li>
            <li data-answer="correct">Higher risk of valve thrombosis compared to warfarin</li>
            <li data-answer="wrong">They interact with valve materials</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Heparins & Low-Molecular-Weight Heparins (LMWHs)</h1>
        <h2>Mechanism of Action</h2>
        <p><b>Unfractionated heparin (UFH)</b> binds <b>antithrombin (AT)</b>, accelerating its inhibition of thrombin (IIa) and Xa (1:1 ratio). <b>LMWHs</b> (enoxaparin, dalteparin) preferentially inhibit Xa over IIa (2-4:1 ratio) due to shorter polysaccharide chains. UFH requires monitoring via <b>aPTT</b>, while LMWHs have predictable dosing (weight-based).</p>

        <h2>Indications</h2>
        <p>UFH is used when rapid reversal may be needed (e.g., <b>cardiac surgery, PCI</b>) or in renal failure (UFH renally cleared). LMWHs are preferred for:</p>
        <ol>
            <li><b>VTE treatment/prophylaxis</b> (superior to UFH for DVT prevention)</li>
            <li><b>Cancer-associated thrombosis</b> (better than warfarin)</li>
            <li><b>Pregnancy</b> (doesn't cross placenta)</li>
        </ol>

        <h2>Pharmacokinetics</h2>
        <p>UFH has <b>zero-order kinetics</b> (saturable cellular binding), short half-life (1-2h), and is reversed by <b>protamine</b>. LMWHs have <b>first-order kinetics</b>, longer half-life (4-7h), and are only partially reversed by protamine. Both are contraindicated in <b>HIT</b> (heparin-induced thrombocytopenia).</p>

        <h2>Side Effects</h2>
        <p>Major risks include:</p>
        <ol>
            <li><b>HIT</b> (Type II: immune-mediated, 5% with UFH, <1% LMWH)</li>
            <li><b>Bleeding</b> (less with LMWH than UFH)</li>
            <li><b>Osteoporosis</b> (long-term use)</li>
            <li><b>Hyperkalemia</b> (via aldosterone suppression)</li>
        </ol>

        <div class="mnemonic">
            <b>Mnemonic: "HEPARIN" for UFH vs LMWH</b><br>
            <b>H</b> - Half-life longer (LMWH)<br>
            <b>E</b> - Efficacy similar<br>
            <b>P</b> - Protamine reverses UFH fully<br>
            <b>A</b> - aPTT monitors UFH<br>
            <b>R</b> - Renal clearance (both)<br>
            <b>I</b> - Injections (both SC/IV)<br>
            <b>N</b> - No monitoring usually for LMWH
        </div>
    </div>

    <div class="question-card">
        <h1>Question 7</h1>
        <p>Why does LMWH have greater anti-Xa than anti-IIa activity compared to UFH?</p>
        <ul class="options" id="options">
            <li data-answer="correct">Shorter polysaccharide chains cannot bridge AT to thrombin</li>
            <li data-answer="wrong">Selective chemical modification during manufacturing</li>
            <li data-answer="wrong">Higher affinity for Xa's active site</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 8</h1>
        <p>A patient develops thrombocytopenia and new thrombosis 5 days after starting UFH. What is the most likely diagnosis?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Disseminated intravascular coagulation (DIC)</li>
            <li data-answer="correct">Heparin-induced thrombocytopenia (HIT)</li>
            <li data-answer="wrong">Immune thrombocytopenic purpura (ITP)</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Other Antithrombotic Agents</h1>
        <h2>Antiplatelet Agents</h2>
        <p>Used primarily for <b>arterial thrombosis</b> (platelet-rich):</p>
        <ol>
            <li><b>Aspirin</b>: Irreversibly inhibits COX-1 â reduced TXA2 (platelet aggregation)</li>
            <li><b>P2Y12 inhibitors</b> (clopidogrel, ticagrelor, prasugrel): Block ADP receptors</li>
            <li><b>GP IIb/IIIa inhibitors</b> (abciximab): Final common pathway blockade (IV use in PCI)</li>
            <li><b>PAR-1 antagonists</b> (vorapaxar): Thrombin receptor inhibition</li>
        </ol>

        <h2>Statins</h2>
        <p>Beyond lipid-lowering, statins have <b>pleiotropic antithrombotic effects</b>:</p>
        <ol>
            <li>Upregulate endothelial <b>NO synthase</b> (vasodilation)</li>
            <li>Reduce <b>tissue factor</b> expression</li>
            <li>Stabilize atherosclerotic plaques</li>
            <li>Modulate platelet reactivity</li>
        </ol>
        <p>These effects contribute to reduced cardiovascular events independent of LDL lowering.</p>

        <h2>Novel Agents</h2>
        <p>Emerging anticoagulants include:</p>
        <ol>
            <li><b>FXI inhibitors</b> (abelacimab): Target contact activation pathway</li>
            <li><b>RNA interference</b> (fitusiran): Reduces antithrombin production</li>
            <li><b>Factor XII inhibitors</b>: May provide thrombosis prevention without bleeding risk</li>
        </ol>
    </div>

    <div class="question-card">
        <h1>Question 9</h1>
        <p>Which antiplatelet agent acts on the final common pathway of platelet aggregation?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Aspirin</li>
            <li data-answer="wrong">Clopidogrel</li>
            <li data-answer="correct">Abciximab</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 10</h1>
        <p>Which statin effect contributes most to its antithrombotic properties?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">LDL cholesterol reduction</li>
            <li data-answer="correct">Endothelial NO synthase upregulation</li>
            <li data-answer="wrong">HDL cholesterol elevation</li>
        </ul>
    </div>

    <div class="placeholder" id="empty">Test</div>

</div>